Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Ausbruch – startet jetzt die massive FDA-Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
161 Leser
Artikel bewerten:
(0)

Leaders in Latin American biopharma innovation lead the program at Biolatam 2016 global life science partnering event Nov. 29-30

CARLSBAD, California and SAN JUAN, Puerto Rico, Oct. 19, 2016 /PRNewswire/ -- The highly anticipated third edition of Biolatam® international life science partnering conference will take place in San Juan, Puerto Rico, November 29-30, 2016. The event, produced by EBD Group and ASEBIO in collaboration with Puerto Rico Science, Technology & Research Trust, will bring over 300 life science dealmakers from pharma, biotech and service companies representing US, Latin American and European entities to Puerto Rico.

Attendees include executives from innovative biotech companies from across Latin America, representing a variety of speciality areas such as health, agrifood, industrials, plus emerging medical device and digital technology companies. Leaders of industry and academia as well as the investment community representing venture capital firms, private equity, and angels will be part of the event as well.

"There is a growing wave of interest in partnerships with Latin American biopharma companies. The success of Biolatam is the response to this interest. The global and regional company executives who attend are eager to connect and gain prime access to this emerging market," said Anna Chrisman, Group Managing Director, EBD Group.

"The commitment of the Puerto Rico Government to innovation, and the country's political and legal stability, its rich biodiversity, as well as the economic strength of many biotechnology-dependent sectors such as foodstuffs, cosmetics, and energy, make Puerto Rico an ideal venue to celebrate Biolatam," said Ion Arocena, General Director of ASEBIO. "ASEBIO and EBD Group are working with Latin American partners to promote business development opportunities in this region. Puerto Rico has an excellent geostrategic position and is a gateway to the US, the world's largest biotech market."

From dealmaking and alliance management to unique financing opportunities, the Biolatam program is designed to equip decision makers with information on the business opportunities in the Latin American market.

Featured speakers at Biolatam 2016 include:

  • Ion Arocena, Managing Director at ASEBIO
  • Abel Baerga-Ortiz, Director, Center for Tropical Biodiversity and Bioprospecting at Puerto Rico Science, Technology and Research Trust
  • Rolando Castro, CEO at Cognitiva IBM Watson Strategic Partner
  • Gabriela Couto, President at CRBioMed - Costa Rican Biotech and Medical Device Association
  • Lucy Crespo, CEO at Puerto Rico Science, Technology & Research Trust
  • Carmen Cuevas Marchante, Director, Research and Development at PharmaMar
  • Kosmas Krestos, Executive Director at Puerto Rico Consortium for Clinical Investigation
  • Iván Lugo-Montes, Executive Director, INDUNIV Research Consortium
  • Andrew Sandford, VP, Global Business Development, Biologics, Catalent Biologics

Register now to attend Biolatam to gain access to Latin America's exclusive life science partnering event.

Additional links and information:

Follow Biolatam 2015 on Twitter: @EBDGroup (hashtag: BLT15) and @BIOLATAM.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe's largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America', the fastest growing partnering event in North America
  • Biotech Showcase', a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® Group
  • Biolatam®, facilitating partnering among global life sciences executives in Latin America's vibrant life science hubs
  • Cell & Gene Exchange, a partnering forum focused on the patient community in cell and gene therapy sectors, co-produced with Alliance for Regenerative Medicine (ARM).

EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

Tune into EBD Group's Insight for timely coverage of news that influences the business strategies of the life science industry.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.